Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (Q54580525)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. |
scientific article |
Statements
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (English)
Priya Rastogi
Marc E Buyse
Samuel A Jacobs
André Robidoux
Marcia K Liepman
Eduardo R Pajon
Philip A Dy
Juan G Posada
Marianne K Melnik
Fanny Piette
Charles E Geyer
Elfetherios P Mamounas
Norman Wolmark
4 May 2011
11
4
228-234